Kathleen is highly experienced in multi-jurisdictional patent litigation having acted in some of the most high-profile patent disputes of the last 20 years.

Kathleen’s career in IP includes over 18 years at Taylor Wessing, training there and then joining the patent litigation team on qualification, and three years as head of the London patent litigation team at Browne Jacobson. She is cited as a leading UK patent litigator by the major legal directories.

Kathleen has advised clients across a variety of industry sectors, substantially in the telecoms, electronics, IT, pharma/biotech, engineering and chemical industries. This includes multi-jurisdictional litigation co-ordination, interim injunctions, infringement and validity litigation in the High Court, Court of Appeal and Supreme Court.

Her work in the telecoms, IT and electronics sectors has concerned patents for various aspects of mobile phones, including speech coding and advice relating to standard essential patents (SEPs) as well as encrypted email, bank card security, optics and semi-conductors. She also has considerable experience in advising in relation to competition law FRAND issues arising in patent litigation concerning SEPs.

Kathleen has advised biotech/pharma and medical device companies throughout her career, in relation to large and small molecule drugs, including SPC aspects, and regulatory issues affecting pharmaceutical companies, and has particular expertise in respect of interim injunctions.

Kathleen also has significant experience advising in relation to competition law aspects associated with patents affecting pharmaceutical companies, particularly the European Commission’s pharma sector enquiry into patent settlement agreements. This includes advising on responses to requests for information from the European Commission, “dawn raids” and advising on the consequences of the Commission’s findings in the inquiry.

Kathleen has enjoyed particular success in interim injunctions in UK patent disputes, calculation and recovery of damages due to interim injunctions, and costs recovery.